- •Uveitis
- •Foreword
- •Preface
- •Dedication
- •Acknowledgments
- •Elements of the Immune System and Concepts of Intraocular Inflammatory Disease Pathogenesis
- •Elements of the immune system
- •Macrophages/monocytes
- •Dendritic cells
- •T cells
- •Major subsets of T cells
- •Cytokines
- •T-cell subsets
- •T-regulatory cells
- •T-cell receptor
- •Chemokines
- •Thymic expression and central immune tolerance
- •B cells
- •Classes of Immunoglobulin
- •Other cells
- •Mast Cells
- •Eosinophils
- •Neutrophils
- •Resident Ocular Cells
- •Complement system
- •Cellular interactions: hypersensitivity reactions
- •Classic immune hypersensitivity reactions
- •Type I
- •Type II
- •Type III
- •Type IV
- •Type V
- •Concepts of disease pathogenesis
- •Immune characteristics of the eye
- •Absence of lymphatic drainage
- •Intraocular microenvironment
- •Anterior Chamber-Associated Immune Deviation (ACAID)
- •Fas-Fas Ligand Interactions and Programmed Cell Death (Apoptosis)
- •Resident Ocular Cells and Immune System
- •Cytokines and Chemokines and the Eye
- •Oral Tolerance
- •Choroidal circulation and anatomy
- •Retina
- •Immunogenetics
- •Class I antigens
- •Class II and class III antigens
- •Histocompatibility lymphocyte antigens
- •Single-nucleotide polymorphisms (SNPs)
- •Epigenetics
- •Immune complex-mediated disease
- •Gene expression profiling
- •Tissue damage in the eye
- •T-cell responses and autoimmunity
- •T-cell receptor and the expression of disease
- •Ocular autoimmunity
- •Uveitogenic antigens
- •Retinal S-Antigen (Arrestin)
- •Interphotoreceptor Retinoid-Binding Protein
- •Recoverin
- •Bovine Melanin Protein
- •Rhodopsin
- •Phosducin
- •Tyrosinase
- •Other Antigens
- •Endotoxin and Other Bacterial Antigens
- •Importance of Antigen Studies
- •Cell adhesion molecules and their role in lymphocyte homing and in disease
- •Immune responses to invading viruses and parasites
- •Suggested Readings
- •References
- •Medical History in the Patient with Uveitis
- •References
- •Sample Uveitis Questionnaire
- •FAMILY HISTORY
- •SOCIAL HISTORY
- •PERSONAL MEDICAL HISTORY
- •MEDICAL HISTORY
- •Examination of the Patient with Uveitis
- •Visual acuity
- •External examination
- •Pupils and extraocular muscles
- •Intraocular pressure measurement
- •Slit-lamp biomicroscopy
- •Conjunctiva
- •Cornea
- •Keratic Precipitates
- •Other Corneal Findings
- •Anterior chamber
- •Iris
- •Anterior chamber angle
- •Lens
- •Vitreous
- •Retina and choroid
- •Optic nerve
- •References
- •Development of a Differential Diagnosis
- •Forming a differential diagnosis
- •Classifying uveitis
- •Is the disease acute or chronic?
- •Is the inflammation granulomatous or nongranulomatous?
- •Is the disease unilateral or bilateral?
- •Where is the inflammation located in the eye?
- •What are the demographics of the patient?
- •What associated symptoms does the patient have?
- •What associated signs are present on physical examination?
- •What is the time course of the disease and response to previous therapy?
- •Case 4-1
- •Case 4-2
- •References
- •Diagnostic Testing
- •Pretest likelihood of disease
- •Receiver operating characteristic (ROC) curve
- •Diagnostic tests for uveitis
- •Laboratory tests
- •Image analysis
- •Skin testing
- •Tissue samples
- •Ancillary ophthalmic tests
- •Electrophysiology
- •Laser interferometry
- •Fluorescein angiography
- •Indocyanine green
- •Laser flare photometry
- •Optical coherence tomography
- •High-frequency ultrasound biomicroscopy and multifrequency ultrasound
- •Fundus autofluorescence
- •Other diagnostic tests
- •Polymerase chain reaction (PCR)
- •Rapid tests for herpes simplex and herpes zoster
- •Bone mineral density studies
- •Genetic testing for steroid-induced glaucoma
- •Neurologic tests
- •References
- •Evidence-Based Medicine in Uveitis
- •Study design
- •Clinical trials in uveitis
- •References
- •Philosophy, Goals, and Approaches to Medical Therapy
- •Goals and philosophy
- •Pain, photophobia, and discomfort
- •Degree and location of inflammatory disease
- •Evaluation of visual acuity and prospect of reversibility
- •Follow-up procedures and standardization of observations
- •General health and age of patient
- •Patient reliability, preferences, and understanding
- •Nonsurgical therapeutic options
- •Corticosteroids
- •Mode of Action
- •Preparations, Dosage Schedules, and Complications
- •Ozurdex.
- •Secondary Effects
- •Cytotoxic agents
- •Alkylating agents
- •Mode of Action
- •Indications and Dosages
- •Secondary Effects
- •Antimetabolites
- •Azathioprine
- •Mode of Action
- •Indications and Dosages
- •Secondary Effects
- •Mycophenolate mofetil
- •Methotrexate
- •Mode of Action
- •Indications and Dosages
- •Secondary Effects
- •Ciclosporin
- •Mode of Action
- •Dosages and Indications
- •Secondary Effects
- •Tacrolimus
- •Mode of Action
- •Indications and Dosages
- •Secondary Effects
- •Lx 211 (Voclosporin)
- •Rapamycin
- •Mode of Action
- •Indications and Dosages
- •Toxicity
- •Antibodies and monoclonal antibodies
- •Daclizumab
- •Etanercept
- •Infliximab (Remicade)
- •Adalimumab (Humira)
- •Efalizumab (Raptiva)
- •Rituximab (Rituxan)
- •Anakinra (Kineret)
- •Alemtuzumab (Campath-1H)
- •Abatacept (Orencia)
- •Intravenous immunoglobulin therapy
- •Oral tolerance
- •Interferon-α
- •Antiviral therapy
- •Aciclovir
- •Ganciclovir
- •Valaciclovir
- •Famciclovir
- •Foscarnet
- •Combined ganciclovir and foscarnet
- •Cidofovir
- •Fomivirsen
- •Colchicine
- •Mode of Action
- •Indications and Dosages
- •Secondary Effects
- •Mydriatic and cycloplegic agents
- •Antitoxoplasmosis therapy
- •Other therapeutic approaches
- •Immunostimulators
- •Plasmapheresis
- •Nonsteroidal antiinflammatory agents
- •References
- •Role of Surgery in the Patient with Uveitis
- •Considerations
- •Removal of band keratopathy
- •Corneal transplantation
- •Cataract surgery
- •Glaucoma surgery
- •Treatment of vitreoretinal disease
- •Laser treatment
- •Photodynamic therapy
- •Diagnostic surgery
- •Anterior chamber paracentesis
- •Chorioretinal biopsy
- •Subretinal surgery
- •Case 8-1
- •References
- •Bacterial and Fungal Diseases
- •Introduction
- •Leprosy
- •Clinical findings
- •Immunology and pathology
- •Therapy
- •Tuberculosis
- •Systemic disease
- •Ocular disease
- •Diagnosis
- •Therapy
- •Other bacterial infections
- •Brucellosis
- •Whipple’s disease
- •Treatment and prognosis
- •Chronic granulomatous disease
- •Fungal disease
- •Neuroretinitis
- •References
- •Spirochetal Diseases
- •Spirochetal infections and the eye
- •Spirochetes
- •Definition
- •Venereal treponemal diseases
- •Syphilis
- •Etiology and Epidemiology
- •Clinical Manifestations
- •Primary syphilis.
- •Secondary syphilis.
- •Latent syphilis.
- •Tertiary syphilis.
- •Benign tertiary syphilis.
- •Cardiovascular syphilis.
- •Neurosyphilis.
- •Congenital syphilis.
- •Ocular Manifestations
- •Diagnosis
- •Prognosis
- •Treatment
- •General recommendations.
- •Approach to Syphilis in Patients with AIDS
- •Nonvenereal treponematoses
- •Endemic syphilis
- •Etiology and Epidemiology
- •Clinical Manifestations
- •Ocular Manifestations
- •Diagnosis
- •Prognosis
- •Treatment
- •Yaws and pinta
- •Ocular Manifestations
- •Diagnosis
- •Prognosis
- •Treatment
- •Borrelia infection
- •Lyme disease
- •Etiology and Epidemiology
- •Clinical Manifestations
- •Ocular Manifestations
- •Diagnosis
- •Prognosis
- •Treatment
- •Relapsing fever
- •Etiology and Epidemiology
- •Clinical Manifestations
- •Ocular Manifestations
- •Diagnosis
- •Prognosis
- •Treatment
- •Leptospirosis
- •Etiology and Epidemiology
- •Clinical Manifestations
- •Ocular Manifestations
- •Weil’s disease
- •Diagnosis
- •Prognosis
- •Treatment
- •Case 10-1
- •References
- •Acquired Immunodeficiency Syndrome
- •Human immunodeficiency virus
- •Epidemiology
- •Diagnosis
- •HIV disease
- •HIV therapy
- •Ocular manifestations of HIV infection
- •Ocular infection
- •Cytomegalovirus retinitis
- •Progression
- •CMV retinitis in the era of highly active antiretroviral therapy
- •Treatment
- •Intravitreal ganciclovir implant
- •Current therapeutic approach to CMV retinitis in the era of HAART
- •Retinal detachment
- •Prognosis
- •Immune recovery uveitis
- •Herpes zoster
- •Pneumocystis jirovecii choroiditis
- •Mycobacterium avium-intracellulare choroiditis
- •Other diseases
- •Drug-related ocular inflammation
- •Case 11-1
- •Case 11-2
- •References
- •Acute retinal necrosis
- •Epidemiology
- •Clinical features
- •Etiology
- •Differential diagnosis
- •Therapy
- •Progressive outer retinal necrosis
- •Diagnosis
- •Differential diagnosis
- •Etiology
- •Therapy
- •Case 12-1
- •Case 12-2
- •References
- •Other Viral Diseases
- •Herpes simplex virus kerititis and keratouveitis
- •Pathogenesis
- •Diagnosis
- •Treatment
- •Herpes zoster ophthalmicus
- •Treatment
- •West Nile virus
- •Epidemiology
- •Diagnosis
- •Clinical description
- •Ophthalmic manifestations
- •Treatment
- •Prognosis
- •Other viral infections
- •Human T-lymphotropic virus type I
- •Case 13-1
- •References
- •Ocular Toxoplasmosis
- •Organism
- •Clinical manifestations
- •Systemic
- •Ocular
- •Decreased Vision
- •Loss of Vision
- •Effects in immunocompromised host
- •Histopathology and immune factors
- •Immune response
- •Inflammatory response
- •Methods of diagnosis
- •Pregnancy
- •Other methods
- •Congenital versus acquired disease
- •Therapy
- •Additional therapeutic approaches
- •Case 14-1
- •Case 14-2
- •Case 14-3
- •Case 14-4
- •References
- •Ocular Histoplasmosis
- •Systemic findings
- •Ocular appearance
- •‘Histo’ spots
- •Maculopathy
- •Peripapillary pigment changes
- •Clear vitreous
- •Etiology and immunology
- •Nonsurgical therapies
- •Laser therapy
- •Subretinal surgery
- •References
- •Toxocara canis
- •Ocular manifestations
- •Histopathology and immune factors
- •Enzyme-linked immunoabsorbent assay
- •Treatment
- •Case 16-1
- •References
- •Onchocerciasis and Other Parasitic Diseases
- •Onchocerciasis
- •Clinical appearance
- •Immune characteristics
- •Therapy
- •Giardiasis
- •Ophthalmomyiasis
- •Cysticercosis
- •Caterpillar hairs
- •Amebiasis
- •Diffuse unilateral subacute neuroretinitis (DUSN)
- •Malaria
- •Seasonal hyperacute panuveitis (SHAPU)
- •References
- •Postsurgical Uveitis
- •Acute bacterial endophthalmitis
- •Chronic bacterial endophthalmitis
- •Fungal endophthalmitis
- •Endogenous endophthalmitis
- •Lens-induced uveitis
- •Toxic anterior segment syndrome (TASS)
- •Laser-induced uveitis
- •Case 18-1
- •References
- •Anterior Uveitis
- •Epidemiology
- •Clinical description
- •Idiopathic anterior uveitis
- •Diagnostic workup
- •Treatment
- •HLA-B27–associated anterior uveitis
- •Epidemiology
- •Demographics and clinical findings
- •Etiology
- •HLA-B27–associated anterior uveitis with systemic disease
- •Ankylosing spondylitis
- •Etiology
- •Treatment
- •Reactive arthritis (Reiter’s syndrome)
- •Juvenile idiopathic arthritis
- •Diagnosis
- •Pathology
- •Differential diagnosis
- •Treatment and prognosis
- •Psoriatic arthropathy
- •Inflammatory bowel disease
- •Whipple’s disease
- •Disease associations
- •Fuchs’ heterochromic iridocyclitis
- •Etiology
- •Treatment and prognosis
- •Kawasaki disease
- •Tubulointerstitial nephritis and uveitis syndrome (TINU)
- •Pathogenesis
- •Glaucomatous cyclitic crisis
- •Schwartz syndrome
- •Anterior segment ischemia
- •Lens-induced uveitis
- •Anterior uveitis associated with AIDS
- •Other disease associations
- •References
- •Scleritis
- •Episcleritis
- •Scleritis
- •Disease associations
- •Other causes of scleritis
- •Diagnostic testing
- •Pathogenesis
- •Differential diagnosis
- •Treatment
- •References
- •Intermediate Uveitis
- •Epidemiology
- •Clinical manifestations
- •Prognosis
- •Differential diagnosis
- •Multiple sclerosis
- •Etiology
- •Treatment
- •Corticosteroids
- •Immunosuppressive agents
- •Surgery
- •Case 21-1
- •Case 21-2
- •References
- •Sarcoidosis
- •Epidemiology
- •Etiology
- •Clinical manifestations
- •Anterior uveitis
- •Posterior segment findings
- •Systemic involvement
- •Pathology
- •Diagnosis
- •Treatment
- •Case 22-1
- •References
- •Sympathetic Ophthalmia
- •Clinical appearance and prevalence
- •Classic presentation
- •Sequelae
- •Tests and immunologic characteristics
- •Dalen–fuchs nodules
- •Preservation of the choriocapillaris
- •Therapy
- •Corticosteroids
- •Immunosuppressive agents
- •Case 23-1
- •Case 23-2
- •References
- •Vogt–Koyanagi–Harada Syndrome
- •Clinical aspects
- •Systemic findings
- •Ocular findings
- •Course of disease
- •Laboratory tests, etiology, and histopathology
- •Antigen-specific and immune responses
- •Vogt–Koyanagi–Harada syndrome versus sympathetic ophthalmia
- •Therapy
- •Cataract extraction
- •Case 24-1
- •Case 24-2
- •References
- •Birdshot Retinochoroidopathy
- •Clinical manifestations
- •Ocular examination and ancillary clinical tests
- •Tests, histology and etiology
- •Therapy
- •Case 25-1
- •Case 25-2
- •References
- •Behçet’s Disease
- •Clinical manifestations
- •Oral aphthous ulcers
- •Skin lesions
- •Genital ulcers
- •Ocular disease
- •Retinal disease
- •Complications
- •Minor criteria
- •Arthritis
- •Vascular alterations
- •Neurologic involvement (neuro-Behçet’s disease)
- •Immunologic and histologic considerations
- •Role of T cells (but other cells count too!)
- •HLA typing and single nucleotide polymorphisms (SNPs)
- •Therapy
- •Systemic corticosteroids
- •Cytotoxic and antimetabolic agents
- •Colchicine
- •Interferon-α
- •Ciclosporin and tacrolimus (FK506)
- •Anti-TNF therapy (infliximab)
- •Other approaches
- •Case 26-1
- •Case 26-2
- •Case 26-3
- •References
- •Retinal Vasculitis
- •Clinical characteristics
- •Ocular vasculitic disorders without systemic disease
- •Eales’ disease
- •Idiopathic retinal vasculitis, aneurysms, and neuroretinitis (IRVAN syndrome)
- •Frosted branch angiitis
- •Scleritis
- •Ocular vasculitic disorders with systemic disease
- •Systemic lupus erythematosus
- •Polyarteritis nodosa
- •Wegener’s granulomatosis
- •Whipple’s disease
- •Inflammatory bowel disease
- •Autoantibodies to Sjögren’s syndrome A antigen
- •Retinal vein occlusion
- •Relapsing polychondritis
- •Viral diseases
- •Multiple sclerosis
- •Tuberculosis
- •Rheumatoid arthritis
- •Kikuchi–Fujimoto disease
- •Susac syndrome
- •Sweet syndrome
- •References
- •Serpiginous Choroidopathy
- •Clinical features
- •Pathology
- •Etiology
- •Differential diagnosis
- •Therapy
- •Case 28-1
- •Case 28-2
- •Case 28-3
- •References
- •White-Dot Syndromes
- •Multiple evanescent white-dot syndrome
- •Clinical findings
- •Laboratory findings
- •Therapy
- •Multifocal choroiditis and panuveitis
- •Clinical findings
- •Punctate inner choroidopathy
- •Laboratory findings
- •Therapy
- •Acute retinal pigment epitheliitis
- •Clinical findings
- •Laboratory findings
- •Therapy
- •Acute posterior multifocal placoid pigment epitheliopathy
- •Clinical findings
- •Etiology
- •Therapy
- •Subretinal fibrosis and uveitis syndrome
- •Clinical findings
- •Laboratory findings
- •Therapy
- •Acute zonal occult outer retinopathy (AZOOR) and the azoor complex diseases
- •Case 29-1
- •Case 29-2
- •Case 29-3
- •References
- •Masquerade Syndromes
- •Intraocular lymphoma
- •Non-Hodgkin’s lymphoma of central nervous system
- •Diagnosis
- •Treatment
- •Systemic Non-Hodgkin’s lymphoma metastatic to eye
- •Lymphoid hyperplasia of uvea
- •Other malignant processes manifesting as uveitis
- •Paraneoplastic syndromes
- •Multiple sclerosis
- •Other nonmalignant conditions
- •References
- •Introduction
- •Age-related macular degeneration
- •Animal work
- •Animal laser model
- •Ccl2 and Ccr2 knockout model
- •Ccl2 and Cx3cr1 double knockout model
- •CEP induced AMD-like disease
- •Human data
- •Autoimmunity
- •Gene associations
- •Macrophages and other cells
- •Histopathology
- •The downregulatory immune environment
- •Should we consider immunotherapy?
- •Diabetic retinopathy
- •Diabetes and the immune process
- •Animal work
- •Human observations
- •Can we begin to think about immune therapy for diabetes and diabetic retinopathy?
- •Glaucoma
- •Autoantibodies and glaucoma
- •Cellular immunity and glaucoma
- •Can immune intervention help alter the course of glaucoma?
- •References
- •Index
dendritic cells of the skin (Langerhans’ cells) where T-cell activation can occur. What is interesting is the migratory nature of these cells: they constantly carry important information to peripheral centers of the immune response. Whether dendritic APCs can activate T cells efficiently in the tissues themselves is an open question and is important to our understanding of immune responses in the eye. Dendritic cells are thought to be the APCs (or one of the major players) in corneal graft rejection. Thus the concept of removing dendritic cells from a graft has been proposed and used in experimental models. However, there is an opposing concept that peripheral immune tolerance, induced by antigens that foster programmed cell death (apoptosis), may depend on presentation of antigen bydendritic cells in the tissue.
T cells
T cells are found in large numbers in the systemic circulation. Lymphocytes are broadly divided into two major categories, T cells and B cells (discussed later). These appellations are based on initial observations in chickens, in which a subgroup of lymphocytes homed to the thymus, where they underwent a maturational process leading to the heterogeneous population now recognized as ‘thymus-dependent’ or T cells. The thymus, the first lymphoid organ to develop, has essentially two compartments, the cortex and the medulla. Within the thymus are found epithelial cells, thymocytes (immature lymphocytes), occasional macrophages, and more mature lymphocytes. The highly cellular cortex is the center of mitoses, with large numbers of immature thymocytes and epithelial cells adhering to each other. As the thymocytes mature to T cells they migrate to the medulla and are ultimately released into the systemic circulation. Major alterations occur to the thymocyte during this maturational process. There is the activation of specific genes needed for only this portion of the lifecycle of the cells. In addition, lifelong characteristics are acquired. These include the development of specific receptors that recognize particular antigens, the acquisition of MHC restriction needed for proper immune interactions, and the acquisition of various T-cell functions, such as ‘killing’ and ‘helping’ other cells. These cells are activated by a complex of structures on their surface. The T-cell receptor (specific to the antigen that is being presented to the cell), the CD3 complex, and the antigen cradled in either an MHC class I or II cassette are needed. Other cofactors are also needed for very robust activation.
Some important qualities possessed by these cells are their immunologic recall or anamnestic capacity; this increases the number of specific cells as well as changing them into a ‘memory’ phenotype. They also have the capacity to produce cellular products called cytokines (Table 1-2). A T cell previously sensitized to a particular antigen can retain this immunologic memory (see below) essentially for its lifetime. With a repeat encounter, this memory response leads to an immune response that is more rapid and more pronounced than the first. Such an example is the positive skin response seen after purified protein derivative (PPD) testing.
The central role of the T cell in the immune system cannot be overemphasized. T cells function as pivotal modulators of the immune response, particularly by helping B-cell
Elements of the immune system
production of antibody and augmenting cell-mediated reactions through further recruitment of immunoreactive cells. T cells also may downregulate or prevent immune reactions through active suppression. In addition to these ‘managerial’ types of roles, some T-cell subsets are known to be cytotoxic and are recognized as belonging to the predominant cells in transplantation rejection crises. The accumulated evidence supports the importance of T cells in many aspects of the intraocular inflammatory process – from the propagation of disease to its subsequent downregulation.
Major subsets of T cells
The functions that have been briefly described are now thought to be carried out by at least three major subsets of T cells, with these cells identified either through functional studies or through monoclonal antibodies directed against antigens present on their surface. It was observed early on that T cells (as well as other cells) manifest myriad different molecules on their surface membranes, some of which are expressed uniquely at certain periods of cell activation or function. It was noted that certain monoclonal antibodies directed against these unique proteins bind to specific subsets of cells, thereby permitting a way to identify them (Table 1-3). The antibodies to the CD3 antigen (e.g., OKT3) are directed against an antigen found on all mature human T cells in the circulation; approximately 70–80% of lymphocytes in the systemic circulation bear this marker. Antibodies to the CD4 antigen (e.g., OKT4) define the helper subgroup of human T cells (about 60–80% of the total T cells). These cells are not cytotoxic but rather aid in the regulation of B-cell responses and in cell-mediated reactions. They are the major regulatory cells in the immune system. These CD4+ cells respond to antigens complexed to MHCs of the class II type. The CD4+ subgroup of cells is particularly susceptible to the human immunodeficiency virus (HIV) of the acquired immunodeficiency syndrome (AIDS), with the percentage of this subset decreasing dramatically as this disease progresses. Further, these helper cells are necessary components of the autoimmune response seen in the experimental models of ocular inflammatory disease induced with retinal antigens (see discussion of autoimmunity later in this chapter). There is a subset of CD4+ cells that also bear IL-2 receptors (CD25) on their surface. In rodents, and possibly also in humans, some T-regulatory cells may bear the CD25 receptor (see below).
Antibodies to the CD8 antigen (i.e., OKT8) distinguish a population that includes cytotoxic T cells, making up about 20–30% of the total number of T cells. (In the older literature it was thought to harbor suppressor cells, but this is no longer thought to be the case). Antibodies directed against the CD8 antigen block class I histocompatibility-associated reactions.
Cytokines
Intercellular communication is in large part mediated by cytokines and chemokines (see below). Cytokines are produced by lymphocytes and macrophages, as well as by other cells. They are hormone-like proteins capable of amplifying an immune response as well as suppressing it. With the activation of a T lymphocyte, the production and release of various lymphokines will occur. One of the most important is IL-2, with a molecular weight of 15 000 Da in humans.
3
|
|
1 |
Part 1 • Fundamentals |
|
|
Chapter |
|
Elements of the Immune System and Concepts of Intraocular Inflammatory Disease Pathogenesis |
|||
|
|
|
|||
|
Table 1-2 Cytokines: An incomplete list |
|
|||
|
Type |
Source |
Target and Effect |
||
|
Interferon-γ |
T cells |
Antiviral effects; promotes expression of MHC II |
||
|
|
|
|
|
Antigens on cell surfaces; increases MΦ tumor killing; inhibits some T-cell proliferation |
|
|
|
|
||
|
Transforming growth |
T cells, resident ocular |
Suppresses generation of certain T cells; involved in ACAID and oral tolerance |
||
|
factor-β |
cells |
|
||
|
|
|
|
||
|
Interleukin |
|
|
||
|
|
|
|
|
|
|
|
IL-1 |
Many nucleated cells, |
T- and B-cell proliferation; fibroblasts – proliferation, prostaglandin production; CNS – fever; bone and |
|
|
|
|
|
high levels in MΦ, |
cartilage resorption; adhesion-molecule expression on endothelium |
|
|
|
|
keratinocyte, |
|
|
|
|
|
endothelial cells, |
|
|
|
|
|
some T and B cells |
|
|
|
|
|
|
|
|
|
IL-2 |
Activated T cells |
Activates T cells, B cells, MΦ, NK cells |
|
|
|
|
|
|
|
|
|
IL-3 |
T cells |
Affects hemopoietic lineage that is nonlymphoid eosinophil regulator; similar function to IL-5 |
|
|
|
|
|
|
GM-CSF |
|
|
|
|
|
|
|
|
IL-4 |
T cells |
Regulates many aspects of B-cell development, affects T cells, mast cells, and MΦ |
|
|
|
|
|
|
|
|
|
IL-5 |
T cells, eosinophils |
Affects hemopoietic lineage that is nonlymphoid, eosinophil regulator: similar function to IL-3 GM-CSF; |
|
|
|
|
|
|
induces B-cell differentiation into IgGand IgM-secreting plasma cells |
|
|
|
|
|
|
|
|
IL-6 |
MΦ T cells fibroblasts; |
B cells – cofactor for Ig production; T cells – co-mitogen; proinflammatory in eye |
|
|
|
|
|
endothelial cells, RPE |
|
|
|
|
|
|
|
|
|
IL-7 |
Stromal cells in bone |
Stimulates early B-cell progenitors; affects immature T cells |
|
|
|
|
|
marrow and thymus |
|
|
|
|
|
|
|
|
|
IL-8 |
NK cells, T cells |
Chemoattractant of neutrophils, basophils, and some T cells; aids in neutrophils adhering to |
|
|
|
|
|
|
endothelium; induced by IL-1, TNF-α, and endotoxin |
|
|
|
|
|
|
|
|
IL-9 |
T cells |
Supports growth of helper T cells; may be enhancing factor for hematopoiesis in presence of other |
|
|
|
|
|
|
cytokines |
|
|
|
|
|
|
|
|
IL-10 |
T cells, B cells, |
Inhibits production of lymphokines by Th1 T cells |
|
|
|
|
|
stimulated MΦ |
|
|
|
|
|
|
|
|
|
IL-11 |
Bone marrow stromal |
Stimulates cells of myeloid, lymphoid, erythroid, and megakaryocytic lines; induces osteoclast |
|
|
|
|
|
cells (fibroblasts) |
formation; enhances erythrocytopoiesis, antigen-specific antibodies, acute-phase proteins, fever |
|
|
|
|
|
|
|
|
IL-12 |
B cells, T cells |
Induces IFN-γ synthesis: augments T-cell cytotoxic activity with IL-2; is chemotactic for NK cells and |
|
|
|
|
|
|
stimulates interaction with vascular endothelium; promotes lytic activity of NK cells; antitumor effects |
|
|
|
|
|
regulate proliferation of Th1 T cells but not Th2 or Th0 |
|
|
|
|
|
|
|
|
IL-13 |
T cells |
Antiinflammatory activity as IL-4 and IL-10; down regulates IL-12 and IFN-α production and thus favors |
|
|
|
|
|
|
Th2 T-cell responses; inhibits proliferation of normal and leukemic human B-cell precursors; monocyte |
|
|
|
|
|
chemoattractant |
|
|
|
|
|
|
|
|
IL-14 |
T cells |
Induces B-cell proliferation, malignant B cells; inhibits immunoglobulin secretion |
|
|
|
|
|
|
|
|
|
IL-15 |
Variety of cells |
Stimulates proliferation of T cells; shares bioactivity of IL-2 and uses components of IL-2 receptor |
|
|
|
|
|
||
|
IFN-α |
Variety of cells |
Antiviral |
||
|
|
|
|
||
|
IFN-β |
Variety of cells |
Antiviral |
||
|
|
|
|
||
|
IFN-γ |
T and NK cells |
Inflammation, activates MΦ |
||
|
|
|
|
||
|
TGF-β |
MΦ, lymphocytes |
Depends on cell interaction |
||
|
|
|
|
||
|
TNF-α |
MΦ |
Inflammation, tumor killing |
||
|
|
|
|
||
|
TNF-β |
T cells |
Inflammation, tumor killing, enhanced phagocytosis |
||
|
|
|
|
|
|
ACAID, anterior chamber-acquired immune deviation; CNS, central nervous system; GM-CSF, granulocyte macrophage colony-stimulating factor; IFN, interferon; MΦ, macrophage; NK, natural killer; RPE, retinal pigment epithelium; TFG, transforming growth factor; TNF, tumor necrosis factor.
The release of this lymphokine can stimulate lymphocyte growth and amplify or augment specific immune responses. Another lymphokine is IFN-γ, an important immunoregulator with the potent capacity to induce class II antigen expression on cells. TGF-β is a ubiquitous protein produced by many cells, including platelets and T cells; it appears to have
the distinct ability to downregulate immune responses, and to play an important role in anterior chamber-acquired immune deviation (ACAID) and oral tolerance. The number of lymphokines that have been purified and for which effects have been described (see Table 1-2 for a partial list) continues to grow rapidly.
4
- #28.03.202681.2 Mб0Ultrasonography of the Eye and Orbit 2nd edition_Coleman, Silverman, Lizzi_2006.pdb
- #
- #
- #
- #28.03.202621.35 Mб0Uveitis Fundamentals and Clinical Practice 4th edition_Nussenblatt, Whitcup_2010.chm
- #
- #
- #28.03.202627.87 Mб0Vaughan & Asbury's General Ophthalmology 17th edition_Riordan-Eva, Whitcher_2007.chm
- #
- #
- #
